TAVR vs isolated SAVR in low-risk patients: 5-year comparative outcomes from the Evolut Low Risk trial
Post hoc subanalysis of the Evolut Low Risk trial comparing 5-year outcomes in 1164 low-risk patients with severe aortic stenosis undergoing isolated aortic valve replacement, either transcatheter (TAVR) or surgical (SAVR).